Lobarstin Enhances Chemosensitivity in Human Glioblastoma T98G Cells
- Authors
- Kim, Sojin; Jo, Sungsin; Lee, Hongki; Kim, Tae Ue; Kim, Il-Chan; Yim, Joung Han; Chung, Heekyoung
- Issue Date
- Dec-2013
- Publisher
- INT INST ANTICANCER RESEARCH
- Keywords
- Lobarstin; glioblastoma; temozolomide; chemosensitivity; DNA repair
- Citation
- ANTICANCER RESEARCH, v.33, no.12, pp.5445 - 5451
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANTICANCER RESEARCH
- Volume
- 33
- Number
- 12
- Start Page
- 5445
- End Page
- 5451
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/161314
- ISSN
- 0250-7005
- Abstract
- Background/Aim: Lobarstin is a metabolite occurring from the Antarctic lichen Stereocaulon alpnum. Human glioblastoma is highly resistant to chemotherapy with temozolomide. Lobarstin was examined for its effect on glioblastoma. Materials and Methods: Temozolomide-resistant T98G cells were subjected to toxicity test with temozolomide and/or lobarstin. DNA damage and recovery was assessed by the alkaline comet assay and expression of DNA repair genes was examined by RT-PCR and western blot analysis. Results: Lobarstin alone at 40 mu M was toxic against T98G, but had no effect in primary human fibroblasts. Co-treatment of lobarstin with temozolomide yielded enhanced toxicity. Temozolomide-alone or with lobarstin co-treatment gave similar extent of DNA damage. However, the recovery was reduced in co-treated cells. Expression of DNA repair genes, O-6-methylguanine-DNA methyltransferase, poly(ADPribose) polymerase I and ligase 3 were reduced in lobarstin-treated cells. Conclusion: Enhanced sensitivity to temozolomide by lobarstin co-treatment may be attributed to reduced DNA repair.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 병리학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/161314)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.